186 related articles for article (PubMed ID: 33255560)
1. Periostin Circulating Levels and Genetic Variants in Patients with Non-Alcoholic Fatty Liver Disease.
Smirne C; Mulas V; Barbaglia MN; Mallela VR; Minisini R; Barizzone N; Burlone ME; Pirisi M; Grossini E
Diagnostics (Basel); 2020 Nov; 10(12):. PubMed ID: 33255560
[TBL] [Abstract][Full Text] [Related]
2. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
Liu YL; Patman GL; Leathart JB; Piguet AC; Burt AD; Dufour JF; Day CP; Daly AK; Reeves HL; Anstee QM
J Hepatol; 2014 Jul; 61(1):75-81. PubMed ID: 24607626
[TBL] [Abstract][Full Text] [Related]
3. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
4. Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis.
Crudele L; De Matteis C; Piccinin E; Gadaleta RM; Cariello M; Di Buduo E; Piazzolla G; Suppressa P; Berardi E; Sabbà C; Moschetta A
JHEP Rep; 2023 Jan; 5(1):100627. PubMed ID: 36561127
[TBL] [Abstract][Full Text] [Related]
5. Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case-control study.
Zhu JZ; Zhu HT; Dai YN; Li CX; Fang ZY; Zhao DJ; Wan XY; Wang YM; Wang F; Yu CH; Li YM
Endocrine; 2016 Jan; 51(1):91-100. PubMed ID: 26362060
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications.
Wong SW; Ting YW; Chan WK
JGH Open; 2018 Oct; 2(5):235-241. PubMed ID: 30483595
[TBL] [Abstract][Full Text] [Related]
7. Cytokines, paraoxonase-1, periostin and non-invasive liver fibrosis scores in patients with non-alcoholic fatty liver disease and persistently elevated aminotransferases: A pilot study.
Milaciu MV; Ciumărnean L; Matei DM; Vesa ȘC; Sabin O; Bocșan IC; Pop RM; Negrean V; Buzoianu AD; Acalovschi M
Exp Ther Med; 2021 May; 21(5):533. PubMed ID: 33815606
[TBL] [Abstract][Full Text] [Related]
8. Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI.
Thompson SM; Garg I; Ehman EC; Sheedy SP; Bookwalter CA; Carter RE; Roberts LR; Venkatesh SK
Br J Radiol; 2018 Dec; 91(1092):20180345. PubMed ID: 30074820
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.
Petrelli F; Manara M; Colombo S; De Santi G; Ghidini M; Mariani M; Iaculli A; Rausa E; Rampulla V; Arru M; Viti M; Lonati V; Ghidini A; Luciani A; Facciorusso A
Neoplasia; 2022 Aug; 30():100809. PubMed ID: 35636146
[TBL] [Abstract][Full Text] [Related]
10. High preoparative levels of serum periostin are associated with poor prognosis in patients with hepatocellular carcinoma after hepatectomy.
Lv Y; Wang W; Jia WD; Sun QK; Huang M; Zhou HC; Xia HH; Liu WB; Chen H; Sun SN; Xu GL
Eur J Surg Oncol; 2013 Oct; 39(10):1129-35. PubMed ID: 23916473
[TBL] [Abstract][Full Text] [Related]
11. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.
Kawanaka M; Tomiyama Y; Hyogo H; Koda M; Shima T; Tobita H; Hiramatsu A; Nishino K; Okamoto T; Sato S; Hara Y; Nishina S; Kawamoto H; Chayama K; Okanoue T; Hino K
Hepatol Res; 2018 Jun; 48(7):521-528. PubMed ID: 29316028
[TBL] [Abstract][Full Text] [Related]
12. Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis.
Villeret F; Dharancy S; Erard D; Abergel A; Barbier L; Besch C; Boillot O; Boudjema K; Coilly A; Conti F; Corpechot C; Duvoux C; Faitot F; Faure S; Francoz C; Giostra E; Gugenheim J; Hardwigsen J; Hilleret MN; Hiriart JB; Houssel-Debry P; Kamar N; Lassailly G; Latournerie M; Pageaux GP; Samuel D; Vanlemmens C; Saliba F; Dumortier J
JHEP Rep; 2023 Mar; 5(3):100668. PubMed ID: 36852108
[TBL] [Abstract][Full Text] [Related]
13. Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver?
Nguyen XK; Zhang J; Chin KL; Bloom S; Nicoll AJ
Nutrients; 2022 Sep; 14(18):. PubMed ID: 36145251
[TBL] [Abstract][Full Text] [Related]
14. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease.
Tovoli F; Ferri S; Piscaglia F
Curr Pharm Des; 2020; 26(32):3909-3914. PubMed ID: 32348210
[TBL] [Abstract][Full Text] [Related]
16. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
17. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.
Wang K; Wei Y; Xu R; Li Y; Mao C
Adv Exp Med Biol; 2022; 1372():157-168. PubMed ID: 35503180
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease.
Lin BZ; Lin TJ; Lin CL; Liao LY; Chang TA; Lu BJ; Chen KY
J Chin Med Assoc; 2021 Jun; 84(6):606-613. PubMed ID: 33871391
[TBL] [Abstract][Full Text] [Related]
19. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
20. Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis.
Kawanaka M; Nishino K; Kawada M; Ishii K; Tanikawa T; Katsumata R; Urata N; Nakamura J; Suehiro M; Haruma K; Kawamoto H
BMC Gastroenterol; 2023 May; 23(1):143. PubMed ID: 37165352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
